Eosinophilia Associated With The Use Of Carfilzomib In A Patient With
Multiple Myeloma: A Case Report and review of literature
Abstract
Multiple myeloma had been an incurable hematological malignancy, recent
advances in novel anti-neoplastic agents, including carfilzomib (CFZ),
have improved the prognosis. CFZ has been reported to have cardiotoxic
effects. Notably, the incidence of peripheral blood eosinophilia was not
described. This is the first report of eosinophilia developing after
CFZ.